Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
326 participants
OBSERVATIONAL
2021-01-05
2021-03-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19 Close Contact Self-Testing Study
NCT04847479
Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere
NCT06928129
Evaluation of a COVID-19 Rapid Diagnostic Test in ER Departments in Mexico: a Multi-center Study
NCT04894760
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test Device
NCT05715515
Rapid Detection of COVID-19 by Portable and Connected Biosensor
NCT04367142
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Positive
Subjects that tested positive for COVID-19 based on the clinical gold standard PCR test.
COVID Detect
The study is determining the efficacy of a new rapid COVID testing method.
Negative
Subjects that tested negative for COVID-19 based on the clinical gold standard PCR test.
COVID Detect
The study is determining the efficacy of a new rapid COVID testing method.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COVID Detect
The study is determining the efficacy of a new rapid COVID testing method.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Written informed consent must be obtained prior to study enrollment.
a. A subject who is eighteen (18) years or older must be willing to give written informed consent and must agree to comply with study procedures.
3. Subject must be able to read and write in English.
Exclusion Criteria
2. The subject has previously participated in this research study.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benjamin S. Abella, MD, MPhil
UNKNOWN
Marcelo Der Torossian Torres, Ph.D.
UNKNOWN
Cesar De La Fuente, Ph.D.
UNKNOWN
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Benjamin S Abella, MD, MPhil
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
844488
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.